Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Glioblastoma × Bevacizumab × Clear all

Phase

Phase 2 75 Phase 1/2 22 Phase 1 16 Phase 3 10 Phase NA 5 Phase EARLY_PHASE1 4 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 10 Colonic Neoplasms 4 Carcinoma, Hepatocellular 4 Carcinoma, Non-Small-Cell Lung 3 Rectal Neoplasms 2 Ovarian Neoplasms 2 Fallopian Tube Neoplasms 2 Astrocytoma 2 Vipoma 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Neoplasms 1 Somatostatinoma 1 Small Cell Lung Carcinoma 1 Recurrence 1 Progression Free Survival 1 Oropharyngeal Neoplasms 1 Oesophagogastric Cancer 1 Neuroendocrine Tumors 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Lymphoid Interstitial Pneumonia 1 Lung Neoplasms 1 Laryngeal Neoplasms 1 Insulinoma 1 Inflammatory Breast Neoplasms 1 Hypopharyngeal Neoplasms 1 Glucagonoma 1

Interventions

Temozolomide 8 Lomustine 4 vocimagene amiretrorepvec 2 Radiation 2 veliparib 1 regorafenib 1 carbon-11 acetate 1 antisecretory factor 1 Sunitinib 1 Standard of Care 1 Radiotherapy 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1 GDC-0084 1 Flucytosine 1 Etoposide 1 Drug Therapy 1 Disulfiram 1 Dianhydrogalactitol 1 DNA 1 Copper 1 Carbon-11 1 Bevacizumab 1 Alkylating Agents 1 AZD1390 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡